Updated:
Adaptive Biotechnologies
Chad Robins co-founded Adaptive Biotechnologies to decode the immune system at scale. The firm split into two public companies in 2024.
Adaptive Biotechnologies
Adaptive Biotechnologies was founded in 2009 by brothers Chad and Harlan Robins, combining Harlan's computational biology expertise with venture backing to productize high-throughput immune sequencing. The company's core scientific asset is a proprietary platform that sequences and maps T-cell and B-cell receptor repertoires, effectively decoding the adaptive immune system's record of past and present disease encounters. The firm is not a traditional asset manager but a publicly traded biotechnology company (NASDAQ: ADPT) that commercializes clinical diagnostics and therapeutic discovery, making it an unusual public-company entity in this context. Adaptive operates across two historically linked business lines: clinical diagnostics — anchored by clonoSEQ, an FDA-cleared assay for detecting minimal residual disease in certain blood cancers — and drug discovery, which applies machine learning to its massive database of immune-receptor sequences to identify therapeutic targets. The company's most notable collaboration was a multi-year agreement with Genentech (Roche) to develop personalized cancer therapies. In 2022, Adaptive restructured its partnership with Microsoft, scaling back a multi-year immunomics mapping project that had been a headline component of its 2019 IPO narrative. In March 2024, the company announced it was splitting into two independent public companies: the diagnostics business retaining the Adaptive Biotechnologies name and ticker, and a new entity called TCR² Therapeutics focused solely on drug discovery. The diagnostic unit received a $125 million investment from OrbiMed as part of the separation. Adaptive reported approximately 1,800 employees at its peak, though headcount was reduced as part of the restructuring. The firm maintains its headquarters in Seattle's South Lake Union neighborhood. The split represents Adaptive's most definitive structural choice: unlike most platform biotechnology companies that retain therapeutic and diagnostic units under one roof while managing internal capital allocation trade-offs, Adaptive opted for a hard separation. This allows each entity to pursue independent financing, partnership, and valuation strategies. The diagnostic business carries a recurring-revenue model from test volumes, while the therapeutics entity inherits the higher-risk, higher-reward drug-development pipeline — a clean capital-markets separation that reflects an unusual willingness to break up a platform rather than manage its internal contradictions.
General information
Firm type
Asset Manager
Year founded
2009
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Seattle
Corporate office
Seattle, WA, United States
Principals
Chad Robins
CEO and co-founder
Harlan Robins
Chief Scientific Officer and co-founder
Sector focus
Frequently asked questions
Who runs investment decisions at Adaptive Biotechnologies?
Adaptive Biotechnologies is not an investment firm — it is a publicly traded biotechnology company (NASDAQ: ADPT). Capital allocation decisions are made by CEO Chad Robins and the board of directors, with the 2024 separation overseen by an independent special committee. The company raises capital through equity offerings, licensing agreements, and strategic partnerships rather than managing third-party investment pools.
How is Adaptive Biotechnologies related to TCR² Therapeutics?
TCR² Therapeutics is the drug-discovery spinout created from Adaptive Biotechnologies' restructuring in March 2024. The new entity combines Adaptive's immuno-oncology pipeline with the TCR² Therapeutics name (a separate company Adaptive acquired or merged assets with). The remaining diagnostic business continues under the Adaptive Biotechnologies name and ticker, focused solely on clonoSEQ and other clinical assays.
What does Adaptive Biotechnologies' diagnostic platform actually measure?
Adaptive's primary diagnostic product, clonoSEQ, uses next-generation sequencing to detect and quantify minimal residual disease (MRD) in patients with certain blood cancers, particularly multiple myeloma and acute lymphoblastic leukemia. The assay identifies unique DNA sequences of cancerous B or T cells and tracks them over time to measure treatment response and detect early relapse, providing a sensitivity level that conventional imaging and pathology cannot match.
What was the scope of Adaptive's partnership with Microsoft?
Announced in 2018 and expanded alongside Adaptive's IPO in 2019, the Microsoft partnership aimed to map the human immunome — the complete catalog of T-cell receptor sequences and their corresponding antigen targets — using Microsoft's Azure cloud and machine learning capabilities. The collaboration was scaled back significantly in 2022, with both companies acknowledging the technical and commercial challenges of building a universal disease-screening diagnostic from immune-sequencing data alone.
How does Adaptive Biotechnologies generate revenue?
The diagnostic side of Adaptive generates revenue through clinical testing volumes for clonoSEQ, which is covered by Medicare and an increasing number of commercial payers. The company also licenses its immune-sequencing platform to pharmaceutical partners for use in clinical trials, including immunogenicity monitoring and patient stratification. The drug-discovery business, now separated as TCR² Therapeutics, is pre-revenue and funded through the OrbiMed investment and partnership agreements.
What investment stages and structures does Adaptive Biotechnologies participate in?
Adaptive Biotechnologies itself is the investee, not the investor. Pre-IPO, it raised venture capital from firms including Casdin Capital, Viking Global Investors, and Matrix Capital Management. As a public company since 2019, it accesses capital through equity offerings and structured partnerships. The 2024 spinout created an investment opportunity in two separately traded public companies with distinct risk profiles, which some healthcare-focused hedge funds and crossover investors have treated as a pair trade.
Which sectors does Adaptive Biotechnologies avoid?
Adaptive's platform is purpose-built for adaptive immune system applications, meaning it naturally excludes areas like metabolic disease, cardiovascular conditions, and central nervous system disorders that lack a clear immune-receptor signature. The company has also avoided the direct-to-consumer testing market — unlike 23andMe or ancestry-focused sequencing companies — maintaining an almost exclusively clinical and pharmaceutical-partner customer base throughout its history.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: